MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced it will release its fourth quarter and full year 2024 financial results after U.S. market close on March 11th, 2025. The company will host a conference call with management to discuss the results at 4:30 p.m. Eastern Time on the same day.
Additionally, MaxCyte management will participate in the 45th Annual TD Cowen Healthcare Conference, delivering a fireside chat on March 3rd at 10:30 a.m. ET. Both events will be accessible via webcast through the company's investor relations website.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), una società tecnologica di piattaforme per l'ingegneria cellulare, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato statunitense il 11 marzo 2025. L'azienda ospiterà una chiamata con la direzione per discutere i risultati alle 16:30, ora orientale, dello stesso giorno.
Inoltre, la direzione di MaxCyte parteciperà alla 45ª Conferenza Annuale TD Cowen sulla Salute, conducendo una chat informale il 3 marzo alle 10:30 ET. Entrambi gli eventi saranno accessibili tramite webcast attraverso il sito web delle relazioni con gli investitori dell'azienda.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), una empresa de tecnología de plataformas de ingeniería celular, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado estadounidense el 11 de marzo de 2025. La empresa llevará a cabo una conferencia telefónica con la dirección para discutir los resultados a las 4:30 p.m. hora del Este del mismo día.
Además, la dirección de MaxCyte participará en la 45ª Conferencia Anual de Salud TD Cowen, realizando una charla informal el 3 de marzo a las 10:30 a.m. ET. Ambos eventos serán accesibles a través de webcast a través del sitio web de relaciones con los inversores de la empresa.
맥사이츠 (NASDAQ: MXCT; LSE: MXCT), 세포 공학 플랫폼 기술 회사가 2024 회계연도 4분기 및 전체 연도 재무 결과를 미국 시장 마감 후 2025년 3월 11일에 발표한다고 발표했다. 회사는 같은 날 동부 표준시로 오후 4시 30분에 경영진과 함께 결과를 논의하는 콘퍼런스 콜을 개최할 예정이다.
또한, 맥사이츠 경영진은 제45회 연례 TD 코웬 헬스케어 컨퍼런스에 참여하여 3월 3일 오전 10시 30분 ET에 파이어사이드 챗을 진행할 예정이다. 두 행사 모두 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있다.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), une société de technologie de plateforme d'ingénierie cellulaire, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la fermeture du marché américain le 11 mars 2025. L'entreprise organisera une conférence téléphonique avec la direction pour discuter des résultats à 16h30, heure de l'Est, le même jour.
De plus, la direction de MaxCyte participera à la 45ème Conférence Annuelle sur la Santé TD Cowen, où elle tiendra une discussion informelle le 3 mars à 10h30 ET. Les deux événements seront accessibles par webcast via le site web des relations avec les investisseurs de l'entreprise.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), ein Unternehmen für Zelltechnik-Plattformtechnologien, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das volle Jahr 2024 nach dem US-Marktabschluss am 11. März 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz mit dem Management abhalten, um die Ergebnisse zu besprechen.
Darüber hinaus wird das Management von MaxCyte an der 45. jährlichen TD Cowen Gesundheitskonferenz teilnehmen und am 3. März um 10:30 Uhr ET ein Fireside-Chat führen. Beide Veranstaltungen werden über ein Webcast über die Investorenbeziehungswebsite des Unternehmens zugänglich sein.
- None.
- None.
ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
Company management will also participate in the following investor conference:
- 45th Annual TD Cowen Healthcare Conference
Fireside Chat on Monday, March 3rd at 10:30 a.m. ET
A live and archived webcast of the Cowen fireside chat will be available on the “Event” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
+1 540-629-3137
jvines@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
FAQ
When will MaxCyte (MXCT) release its Q4 and full year 2024 earnings?
What time is MaxCyte's (MXCT) Q4 2024 earnings conference call?
When is MaxCyte (MXCT) presenting at the TD Cowen Healthcare Conference?
Where can investors access MaxCyte's (MXCT) earnings call webcast?
